Search research articles
Contact Us
Filters
Showing results (31-40 of 110) with videos related to
Page
of 11
Sort By:
International Journal of Hygiene and Environmental Health
|
February 9, 2025
"Is my tap water safe to drink?": Examining the quality of a national sample of United States drinking water reports
Kayla Iuliano, Mary Fox, John H Munroe, et al.
Value in Health Regional Issues
|
April 29, 2018
Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore
Gilberto Lopes, Thomas Burke, James Pellissier, et al.
JCO Clinical Cancer Informatics
|
January 13, 2021
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data
Thomas Jemielita, Xiaoyun Nicole Li, Bilal Piperdi, et al.
Lancet (London, England)
|
October 6, 2017
Tranexamic acid for post-partum haemorrhage in the WOMAN trial
Suellen Miller, Thomas Burke, José M Belizán, et al.
Immunotherapy
|
November 28, 2019
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, et al.
Environmental Health Perspectives
|
October 9, 2004
Identifying priority health conditions, environmental data, and infrastructure needs: a synopsis of the Pew Environmental Health tracking project
Jill Litt, Nga Tran, Kristen Chossek Malecki, et al.
Cancers
|
December 9, 2020
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Plos One
|
November 9, 2018
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
Vamsidhar Velcheti, Pallavi D Patwardhan, Frank Xiaoqing Liu, et al.
Analytical and Bioanalytical Chemistry
|
March 1, 2014
Multiplex detection of disease biomarkers using SERS molecular sentinel-on-chip
Hoan T Ngo, Hsin-Neng Wang, Thomas Burke, et al.
Immunotherapy
|
January 25, 2022
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 110) with videos related to
Sort By:
Page
of 11
International Journal of Hygiene and Environmental Health
|
February 9, 2025
"Is my tap water safe to drink?": Examining the quality of a national sample of United States drinking water reports
Kayla Iuliano, Mary Fox, John H Munroe, et al.
Value in Health Regional Issues
|
April 29, 2018
Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore
Gilberto Lopes, Thomas Burke, James Pellissier, et al.
JCO Clinical Cancer Informatics
|
January 13, 2021
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data
Thomas Jemielita, Xiaoyun Nicole Li, Bilal Piperdi, et al.
Lancet (London, England)
|
October 6, 2017
Tranexamic acid for post-partum haemorrhage in the WOMAN trial
Suellen Miller, Thomas Burke, José M Belizán, et al.
Immunotherapy
|
November 28, 2019
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, et al.
Environmental Health Perspectives
|
October 9, 2004
Identifying priority health conditions, environmental data, and infrastructure needs: a synopsis of the Pew Environmental Health tracking project
Jill Litt, Nga Tran, Kristen Chossek Malecki, et al.
Cancers
|
December 9, 2020
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Plos One
|
November 9, 2018
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
Vamsidhar Velcheti, Pallavi D Patwardhan, Frank Xiaoqing Liu, et al.
Analytical and Bioanalytical Chemistry
|
March 1, 2014
Multiplex detection of disease biomarkers using SERS molecular sentinel-on-chip
Hoan T Ngo, Hsin-Neng Wang, Thomas Burke, et al.
Immunotherapy
|
January 25, 2022
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Page
of 11